Aripiprazole IM Depot

DRUG9 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Beijing Research Institute

Conditions

Schizophrenia

Phase 1

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

CompletedNCT01552772

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2012-01-31End: 2012-04-30Updated: 2014-10-10

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

CompletedNCT01646827

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2012-05-31End: 2013-04-30Updated: 2014-07-31

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

CompletedNCT01870999

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2007-11-30End: 2008-10-31Updated: 2014-01-22

PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia

CompletedNCT03285503

Otsuka Beijing Research InstituteSchizophrenia

Start: 2018-08-17End: 2019-10-14Updated: 2020-07-10

Aripiprazole IM Depot for Chinese Patients With Schizophrenia

CompletedNCT03287505

Otsuka Beijing Research InstituteSchizophrenia

Start: 2017-06-23End: 2019-11-08Updated: 2020-12-29

Phase 3

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

CompletedNCT00731549

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2008-12-31End: 2013-11-30Updated: 2014-11-26

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

CompletedNCT01663532

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2012-10-31End: 2013-09-30Updated: 2015-02-16

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

CompletedNCT01683058

Otsuka Pharmaceutical Development & Commercialization, Inc.Schizophrenia

Start: 2013-01-31End: 2014-02-28Updated: 2015-03-31

Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia

CompletedNCT03172871

Otsuka Beijing Research InstituteSchizophrenia

Start: 2017-05-15End: 2019-09-30Updated: 2020-12-29

Related Papers

Single- and multiple-dose pharmacokinetics, safety, and tolerability of Aripiprazole once-monthly, long-acting intramuscular injection for Chinese adults with schizophrenia.

2025-10-01

Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.

2022-01-0610 citations

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies.

2019-06-245 citations

F118. EFFECT OF ARIPIPRAZOLE ONCE MONTHLY ON PERSONAL AND SOCIAL FUNCTIONING OF PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSES OF ACUTE AND LONG-TERM MAINTENANCE STUDIES

Schizophrenia Bulletin2019-04-01

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.

2017-04-0127 citations

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia

The Journal of Clinical Psychiatry2014-08-19103 citations

Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole

Current Medical Research and Opinion2013-07-0328 citations